Bendamustine-based chemotherapy induces high CR rate in relapsed HLJuly 8, 2016Indolent LymphomaAggressive Lymphomas
Pembrolizumab shows signs of efficacy in relapsed/refractory classical Hodgkin lymphomaJuly 5, 2016Aggressive Lymphomas
Follicular lymphoma with histologic transformation may merit ASCTJune 14, 2016Indolent LymphomaAggressive Lymphomas
Mogamulizumab achieves objective responses in relapsed/refractory adult T-cell leukemia-lymphomaJune 10, 2016Aggressive Lymphomas
Alemtuzumab plus CHOP didn’t boost survival in elderly patients with peripheral T-cell lymphomasJune 10, 2016Aggressive Lymphomas
Epstein-Barr virus DNA in plasma reliably detects EBV-positive lymphoproliferative disordersMay 11, 2016Indolent LymphomaAggressive Lymphomas
Dose-escalated blinatumomab plus dexamethasone induced responses in relapsed/refractory DLBCLApril 22, 2016Aggressive Lymphomas
FDG-PET guides need for eBEACOPP in advanced Hodgkin’sApril 12, 2016Indolent LymphomaAggressive Lymphomas
OTX015 dose for lymphoma narrowed in phase 1 studyApril 10, 2016Indolent LymphomaAggressive Lymphomas
Temsirolimus results in good but short-duration responses in primary CNS lymphomaMarch 14, 2016Aggressive Lymphomas
Expert panel issues guidelines for treatment of hematologic cancers in pregnancyDecember 1, 2015Aggressive LymphomasIndolent Lymphoma
